Acute traumatic coagulopathy has traditionally been explained by the paradigm of an acquired disorder in the coagulation system through loss or impaired function of coagulation proteases and platelets. However, severe trauma leads to massive haemorrhage with activation and subsequent exhaustion of the coagulation system. Dilution from fluid resuscitation results in an additional relative deficiency of coagulation factors and platelets. Finally, physical factors such as acidaemia and hypothermia further compromise coagulation proteases and platelet function, worsening the evolving coagulopathy.
Recent studies have shown that nearly 25% of trauma patients present with a clinically significant and outcome relevant coagulopathy upon arrival in the emergency department 4 . Interestingly, this early coagulopathy occurred prior to any significant consumption or fluid administration and in absence of a relevant acidaemia or hypothermia. Therefore, it has been postulated that the early coagulopathy after trauma be physiologically and mechanistically distinct from the above-mentioned coagulopathy. This acute coagulopathy of trauma, also called endogenous acute coagulopathy (EAC) 5 or acute coagulopathy of trauma and shock (ACoTS) 6 is driven by the combinations of tissue trauma and shock with systemic hypoperfusion. Thereby, the anticoagulant thrombomodulin protein C pathway is overtly getting activated, resulting in reduced pro-coagulatory potential and increased fibrinolytic activity [7] [8] . Once protein C is being activated through a thrombinthrombomodulin dependent reaction, activated protein C (aPC) exerts its profound anticoagulant effects by irreversibly inactivating factors Va and VIIIa. In addition to its direct inhibition of fibrin formation, aPC resolves already formed clots through its derepression of fibrinolysis by direct inhibition of plasminogen activator inhibitor 1 [9] [10] .
After major trauma, surgeons and anaesthesiologists thus are facing a dual problem:
There is the physical damage including vascular injury with "surgical" haemorrhage and frequently there is a component of coagulopathy with "coagulopathic" bleeding products should be used for treatment, given the hazards, risks, unknowns and costs of allogeneic blood products, factor concentrates and anti-fibrinolytics.
A first option to boost blood coagulation following major trauma is to administer "massive transfusion packages" with a fixed, and these days, high fresh frozen plasma (FFP) to red blood cell (RBC) ratio, some even including platelets 11 . The apparent success of such algorithms in improving survival of US Army combat victims has been described several times 1 . However, there are also studies, in which no benefit of a high FFP:RBC on survival was found 12-13 , and there is an important study showing that the introduction of "massive transfusion packages" resulted in a significant reduction of mortality without a change of the 24h FFP:RBC ratio 14 .
Interestingly, in this study FFP (169 min vs. 254 min) and platelets (241 min vs. 418 min) were administered much earlier following the introduction of "massive transfusion packages" 14 . There are several important aspects to consider when interpreting results of studies showing a benefit of a high FFP:RBC ratio in traumatized patients: data are retrospective and primarily refer to young, previously healthy male patients with penetrating injuries. In addition, the FFP:RBC ratio usually is calculated for the first 24h of treatment. Therefore, there may be a significant selection bias in that clinicians allocated most resources including FFP to those patients most likely to survive 15 . There may also be a survivor bias in that those with the worst injury and bleeding died too early to receive a high number of FFP [15] [16] . In addition, FFP transfusion is associated with adverse effects such as increased incidence of nosocomial infections 17 , multiple organ failure 16 , lung injury [15] [16] and potentially mortality 15, 18 . Therefore, although the use of FFP is suggested in massive bleeding, neither the recently published AABB guidelines 19 nor the updated European guideline on the management of bleeding following major trauma 1 recommends for transfusion of plasma at a FFP:RBC ratio of 1:3 or more.
A second option to early and individually optimize blood coagulation following major trauma is to assess each trauma patient's blood coagulation on admission in the emergency room and throughout the surgery with point of care viscoelastic coagulation monitoring (be it thrombelastography, TEG®, Haemonetics Corp.,
formerly Haemoscope or rotational thrombelastometry, ROTEM®, tem International GmbH, formerly Pentapharm) 20 . These bed-side devices allow analysing the entire blood coagulation within 10-15 min 21 including the detection of (hyper)fibrinolysis [7] [8] .
With this information, coagulation can be readily and individually optimized, for example with anti-fibrinolytics and blood coagulation factor concentrates and later, if necessary with labile blood products. With such an algorithm the use of RBC, FFP and platelets can be significantly reduced 22 and survival of trauma patients significantly improved 23 . The observed mortality in the study by Schoechl et al. was
24.4% which was significantly lower than the expected mortality based on the trauma injury severity score (TRISS) of 33.7% 23 .
Fibrinogen may indeed be the key element of blood coagulation and the one element that is getting critically low first 1 . In addition, fibrin polymerization is compromised by artificial colloids which are frequently used in the initial resuscitation of trauma victims. Interestingly, this form of blood coagulation compromise can be reversed by the administration of fibrinogen 24 . Therefore, aiming at functional fibrinogen levels as assessed by thrombelastometry [22] [23] , appears reasonable and is also proposed by the updated European guideline on the management of bleeding following major 
